Curcumin attenuates potassium oxonate-induced hyperuricemia and kidney inflammation in mice

Chen, Yonger; Li, Cantao; Duan, Shuni; Yuan, Xin; Liang, Jian; Hou, Shaozhen

doi:10.1016/j.biopha.2019.109195

Cited by 114 publications

(56 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Adding curcumin to the diet of hyperuricemia mice can restore normal antioxidant enzyme activities (SOD, GPx) and reduce the accumulation of MDA in serum [24]. Previous research has found that IUGR impaired antioxidant defense system and increased oxidative stress by decreasing the activities of antioxidant enzymes, such as GPx and Cu-Zn SOD [25].…”

Section: Discussionmentioning

confidence: 98%

Curcumin Alleviates IUGR Jejunum Damage by Increasing Antioxidant Capacity through Nrf2/Keap1 Pathway in Growing Pigs

Yan

Zhang

Han

et al. 2019

Animals

View full text Add to dashboard Cite

The purpose of this study was to explore the effects of curcumin on IUGR jejunum damage. A total of 24 IUGR and 12 normal-birth weight (NBW) female crossbred (Duroc × Landrace × Large White) piglets were randomly assigned into three groups at weaning (26 days): IUGR group, NBW group, and IUGR + CUR group, which were fed diets containing 0 mg/kg (NBW), 0 mg/kg (IUGR) and 200 mg/kg (IUGR + CUR) curcumin from 26 to 115 days of age. Results showed that dietary supplementation with 200 mg/kg curcumin significantly increased the total superoxide dismutase (T-SOD) activity and decreased the malondialdehyde (MDA) content in the jejunum of IUGR pigs (p < 0.05). Results of real-time PCR showed that the IUGR + CUR group significantly increased the gene expression of NF-E2-related factor 2 (Nrf2) (p < 0.05), and increased the glutamate-cysteine ligase catalytic subunit (GCLC), superoxide dismutase 1 (SOD1), glutamate-cysteine ligase modifier subunit (GCLM), and NAD(P)H quinone dehydrogenase 1 (NQO1) mRNA expression compared with the IUGR group (p < 0.05). Western blot results showed that dietary supplementation with 200 mg/kg curcumin significantly increased the protein levels of Nrf2 and NQO1. Compared with the IUGR group, pigs in IUGR + CUR group showed significantly decreased the levels of tumor necrosis factor-α (TNFα), interleukin-6 (IL-6), and interferon gamma (IFNγ) (p < 0.05), and increased the interleukin-2 (IL-2) level (p < 0.05). Dietary supplementation with 200 mg/kg curcumin significantly reduced cysteinyl aspartate specific proteinase 3 (caspase3), BCL2-associated X protein (bax), B-cellCLL/lymphoma 2 (bcl2), and heat-shock protein 70 (hsp70) mRNA expression, and increased occludin (ocln) mRNA expression (p < 0.05). In conclusion, dietary supplementation with 200 mg/kg curcumin can alleviate jejunum damage in IUGR growing pigs, through Nrf2/Keap1 pathway.

show abstract

Section: Discussionmentioning

confidence: 98%

Curcumin Alleviates IUGR Jejunum Damage by Increasing Antioxidant Capacity through Nrf2/Keap1 Pathway in Growing Pigs

Yan

Zhang

Han

et al. 2019

Animals

View full text Add to dashboard Cite

show abstract

“…Later, Chen et al reported its in vivo activity on potassium oxonate-induced hyperuricemia mice. Oral administration in a dose of 20 or 40 mg/kg leads to a decrease of serum UA and an effective inhibition of serum and liver XO levels and to a reduction of kidney inflammation by NLRP3 inflammasome suppression [62]. α,β-Unsaturated cyclohexanone and cyclopentanone analogues of curcumin ( Figure 17 Evidence-Based Complementary and Alternative Medicine levels in a hyperuricemic in vivo model.…”

Section: Phenolic Compounds and Analoguesmentioning

confidence: 99%

From Xanthine Oxidase Inhibition to In Vivo Hypouricemic Effect: An Integrated Overview of In Vitro and In Vivo Studies with Focus on Natural Molecules and Analogues

Serrano

Figueiredo

Almeida

et al. 2020

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

Hyperuricemia is characterized by elevated uric acid (UA) levels on blood, which can lead to gout, a common pathology. These high UA levels are associated with increased purine ingestion and metabolization and/or its decreased excretion. In this field, xanthine oxidase (XO), by converting hypoxanthine and xanthine to UA, plays an important role in hyperuricemia control. Based on limitations and adverse effects associated with the use of allopurinol and febuxostat, the most known approved drugs with XO inhibitory effect, the search for new molecules with XO activity is growing. However, despite the high number of studies, it was found that the majority of tested products with relevant XO inhibition were left out, and no further pharmacological evaluation was performed. Thus, in the present review, available information published in the past six years concerning isolated molecules with in vitro XO inhibition complemented with cytotoxicity evaluation as well as other relevant studies, including in vivo hypouricemic effect, and pharmacokinetic/pharmacodynamic profile was compiled. Interestingly, the analysis of data collected demonstrated that molecules from natural sources or their mimetics and semisynthetic derivatives constitute the majority of compounds being explored at the moment by means of in vitro and in vivo animal studies. Therefore, several of these molecules can be useful as lead compounds and some of them can even have the potential to be considered in the future clinical candidates for the treatment of hyperuricemia.

show abstract

“…At the same time, the treatment with curcumin effectively inhibited serum and hepatic levels of xanthine oxidase (XOD) and increased the activity of antioxidant enzymes, such as SOD and GSH-Px. 57 The rat models of chronic kidney disease (CKD) were treated with theracurmin as a new formulation of curcumin to investigate the cardiovascular effects. Theracurmin was able to improve the structural and functional manifestations of heart damage along with renal failure in these rats by inhibiting heart NLRP3 inflammasome and subsequently inhibiting IL-1β production.…”

Section: Effect Of Curcumin On Inflammasome Suppression In Kidney Dmentioning

confidence: 99%

COVID‐19: A Case for Inhibiting NLRP3 Inflammasome, Suppression of Inflammation with Curcumin?

Saeedi-Boroujeni

Mahmoudian-Sani

Bahadoram

et al. 2020

Basic Clin Pharma Tox

View full text Add to dashboard Cite

, the SARS-CoV-2 virus has infected more than 27 million people and left more than 800 000 victims. According to statistics, a high percentage of patients with COVID-19 recover and only a small percentage of them succumb to death. Studies have documented the important role of the immune system in determining the fate of COVID-19 patients. Observations have so far shown that destructive and severe inflammation is the leading cause of death in patients with COVID-19. 1 Significant increases in the levels of inflammatory cytokines (TNF, IL-1β, IL-6, IL-8), colony-stimulating factors (G-CSF and GM-CSF) and inflammatory chemokines (MCP1, IP10 and MIP1α) and the destructive role of inflammatory monocytes and macrophages indicate the role of inflammation in COVID-19 pathogenesis. 2,3 Acute respiratory distress syndrome (ARDS) and cytokine storm are the two main causes of severe COVID-19. 1

show abstract

Curcumin attenuates potassium oxonate-induced hyperuricemia and kidney inflammation in mice

Cited by 114 publications

References 28 publications

Curcumin Alleviates IUGR Jejunum Damage by Increasing Antioxidant Capacity through Nrf2/Keap1 Pathway in Growing Pigs

Curcumin Alleviates IUGR Jejunum Damage by Increasing Antioxidant Capacity through Nrf2/Keap1 Pathway in Growing Pigs

From Xanthine Oxidase Inhibition to In Vivo Hypouricemic Effect: An Integrated Overview of In Vitro and In Vivo Studies with Focus on Natural Molecules and Analogues

COVID‐19: A Case for Inhibiting NLRP3 Inflammasome, Suppression of Inflammation with Curcumin?

Contact Info

Product

Resources

About